Vitamin D deficiency does not affect how well antibiotics work for nontuberculous mycobacterial lung infections, according to a 2026 study of 485 patients. Gram Research analysis found that 42.4% of patients with low vitamin D improved after 6 months of treatment compared to 45.6% with normal vitamin D—a difference too small to matter. Instead, following prescribed treatment guidelines was nearly 4 times more important for recovery success.
Researchers studied 485 patients with a serious lung infection caused by nontuberculous mycobacteria to see if vitamin D deficiency affected how well treatment worked. According to Gram Research analysis, about 45% of patients showed improvement after 6 months of treatment, regardless of whether they had low vitamin D levels. The study found that following treatment guidelines was much more important for recovery than vitamin D status. This challenges earlier beliefs that vitamin D deficiency might make these infections harder to treat.
Key Statistics
A 2026 cohort study of 485 patients with nontuberculous mycobacterial lung disease found that vitamin D deficiency did not affect 6-month treatment success rates, with 42.4% of deficient patients improving versus 45.6% of non-deficient patients (p = 0.651).
According to research reviewed by Gram, patients with nontuberculous mycobacterial lung infections who received guideline-based antibiotic treatment were 3.78 times more likely to show improvement than those with vitamin D deficiency (adjusted odds ratio 3.781; p < 0.001).
In a 2026 multicenter study of 485 treated patients, vitamin D deficiency was not independently associated with time to culture conversion, with an adjusted hazard ratio of 1.031 (95% CI 0.721-1.475; p = 0.868).
A 2026 analysis of 485 patients found that only 20.4% had vitamin D deficiency, yet the overall 6-month culture conversion rate was 44.9%, with no significant difference between deficient and non-deficient groups.
The Quick Take
- What they studied: Whether having low vitamin D levels affects how well antibiotics work to treat a serious lung infection caused by nontuberculous mycobacteria (NTM).
- Who participated: 485 patients with an average age of 64 years, mostly women (73%), who were being treated for lung infections at multiple hospitals in South Korea between 2022 and 2025. About 1 in 5 patients had vitamin D deficiency.
- Key finding: Treatment success rates were nearly identical between patients with low vitamin D (42.4%) and normal vitamin D (45.6%), with no meaningful difference. Following proper treatment guidelines was far more important—patients on guideline-based treatment were nearly 4 times more likely to improve.
- What it means for you: If you have this type of lung infection, your vitamin D level probably won’t determine whether antibiotics work for you. Sticking to your prescribed treatment plan matters much more. However, maintaining adequate vitamin D is still important for overall health and immune function.
The Research Details
This was a prospective cohort study, meaning researchers followed real patients over time rather than randomly assigning them to different treatments. They collected information from 485 patients with nontuberculous mycobacterial lung disease who had their vitamin D levels measured at the start of treatment and were tracked for 6 months. Vitamin D deficiency was defined as having less than 20 nanograms per milliliter of 25-hydroxyvitamin D in the blood—a standard medical cutoff.
The researchers compared how many patients in each group (low vitamin D vs. normal vitamin D) showed improvement on their cultures (lab tests that detect bacteria). They used statistical methods to account for other factors that might affect treatment success, like age, gender, and type of infection. They also measured how long it took patients to show improvement, not just whether they improved.
This study design is important because it reflects real-world treatment of actual patients rather than laboratory conditions. By following patients over time and measuring multiple outcomes, the researchers could see the full picture of how vitamin D status affects treatment. The use of statistical adjustments helps isolate vitamin D’s effect from other factors that influence recovery.
This study has several strengths: it included a large number of patients (485), used standardized vitamin D measurements, tracked patients prospectively, and adjusted for multiple confounding factors. The study was conducted across multiple hospitals, making results more generalizable. However, the study was observational rather than experimental, so it can show associations but not prove cause-and-effect. The relatively short follow-up period (6 months) means we don’t know about longer-term outcomes.
What the Results Show
The overall success rate for treatment was 44.9%—meaning about 45 out of every 100 patients showed improvement after 6 months. When comparing the two groups, patients with vitamin D deficiency had a 42.4% success rate while those with normal vitamin D had a 45.6% success rate. This 3.2 percentage point difference was not statistically significant, meaning it could easily have occurred by chance.
When researchers used advanced statistical methods to account for age, sex, and other factors, vitamin D deficiency still showed no meaningful association with treatment success. The adjusted odds ratio was 1.091, which is very close to 1.0 (the number that means no effect). The confidence interval (0.662-1.797) crossed 1.0, confirming the lack of a real effect.
In contrast, patients who received guideline-based treatment—meaning they followed the recommended antibiotic regimens—were 3.78 times more likely to show improvement. This was a strong, statistically significant finding (p < 0.001), showing that treatment adherence matters far more than vitamin D status.
The study also measured time to conversion (how quickly patients improved) using survival analysis methods. Again, vitamin D deficiency showed no association with how fast patients improved. The adjusted hazard ratio was 1.031, essentially showing no difference between groups. These consistent findings across multiple outcome measures strengthen the conclusion that vitamin D status doesn’t independently affect treatment outcomes in this population.
Earlier research suggested that vitamin D deficiency might impair immune responses to mycobacterial infections, which led scientists to hypothesize it would worsen treatment outcomes. This study challenges that assumption in the context of treated patients. The finding aligns with other recent research showing that while vitamin D supports immune function, its deficiency may not be the limiting factor in treatment success when patients receive appropriate antibiotics. The strong effect of guideline-based treatment confirms what clinical experience has shown: proper medication regimens are the primary determinant of success.
This study has several important limitations. First, it’s observational, so it can identify associations but not prove that vitamin D deficiency causes better or worse outcomes. Second, the study only followed patients for 6 months—we don’t know if vitamin D status affects longer-term outcomes or relapse rates. Third, the study was conducted in South Korea, so results may not apply equally to other populations with different genetics or environmental factors. Fourth, the study didn’t measure vitamin D supplementation during treatment, so we don’t know if patients who started with deficiency received supplements that might have affected outcomes. Finally, about 80% of patients had normal vitamin D levels, which limits statistical power to detect effects in the deficient group.
The Bottom Line
If you have nontuberculous mycobacterial lung disease, focus on taking your prescribed antibiotics exactly as directed—this is the strongest predictor of treatment success. While maintaining adequate vitamin D is important for overall health, it doesn’t appear to be critical for this specific treatment outcome. Discuss vitamin D supplementation with your doctor as part of general health maintenance, but don’t expect it to replace or enhance antibiotic therapy. (Confidence level: Moderate—based on a well-designed cohort study, but observational rather than experimental.)
This research is most relevant to patients with nontuberculous mycobacterial lung infections and their doctors. It’s also important for public health officials and researchers studying mycobacterial diseases. People without this specific infection shouldn’t change their vitamin D practices based on this study. Healthcare providers should use this finding to reassure patients that vitamin D deficiency won’t prevent treatment from working, reducing unnecessary anxiety.
Treatment success is typically assessed at 6 months, as measured in this study. Most patients who will respond to antibiotics show improvement within this timeframe. However, some infections may take longer to resolve, so discuss realistic timelines with your healthcare provider based on your specific situation.
Frequently Asked Questions
Does low vitamin D make it harder to treat nontuberculous mycobacterial lung infections?
No. A 2026 study of 485 patients found that vitamin D deficiency did not affect treatment success rates—42.4% of deficient patients improved versus 45.6% of non-deficient patients. Following prescribed antibiotics matters much more than vitamin D status.
Should I take vitamin D supplements if I have a mycobacterial lung infection?
Discuss this with your doctor as part of general health maintenance, but don’t expect vitamin D supplements to improve your infection treatment. Research shows that taking your antibiotics exactly as prescribed is what determines whether treatment works.
What’s the most important factor for treating nontuberculous mycobacterial infections?
Following guideline-based antibiotic treatment is far more important than vitamin D status. Patients on proper treatment regimens were 3.78 times more likely to improve, making medication adherence your top priority.
Can vitamin D deficiency prevent me from recovering from a mycobacterial lung infection?
Vitamin D deficiency alone does not prevent recovery. A 2026 study found nearly identical recovery rates between patients with low and normal vitamin D levels. Your treatment success depends primarily on taking prescribed antibiotics consistently.
How long does it take to see improvement from mycobacterial lung infection treatment?
Most patients show improvement within 6 months of starting appropriate antibiotics. Vitamin D status doesn’t affect how quickly you improve. Discuss realistic timelines with your healthcare provider based on your specific infection type and severity.
Want to Apply This Research?
- Track antibiotic adherence daily (did you take all doses as prescribed?) and record any culture test results at 3-month and 6-month checkpoints. This helps identify whether treatment is working and ensures you’re following the regimen that research shows matters most.
- Set daily medication reminders in your app to ensure you never miss a dose of your prescribed antibiotics. The research shows that following treatment guidelines is nearly 4 times more effective than any other factor, so perfect adherence should be your priority.
- Create a long-term tracking dashboard showing your antibiotic adherence percentage, culture conversion status at each checkup, and any side effects. Share this with your healthcare provider at each visit to ensure you’re on track and to discuss any barriers to adherence.
This research applies specifically to patients with nontuberculous mycobacterial pulmonary disease receiving antibiotic treatment. The findings do not apply to other infections or conditions. Vitamin D deficiency may still affect other aspects of health and immune function. Always consult with your healthcare provider before making changes to your treatment plan or starting supplements. This article summarizes research findings and should not replace professional medical advice. If you have symptoms of lung infection or are being treated for mycobacterial disease, work closely with your doctor to monitor your condition and ensure you’re following the treatment plan most likely to help you recover.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.